CATALYST PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $589.0M | $491.7M | $398.2M | $214.2M | $140.8M |
| Cost of revenue | $87.3M | $68.8M | $52.0M | $34.4M | $21.9M |
| Selling, general & administrative | $193.8M | $177.7M | $133.7M | $57.1M | $49.6M |
| Research and development | $12.7M | $12.6M | $93.2M | $19.8M | $16.9M |
| Operating expenses | $206.5M | $190.4M | $226.9M | $76.9M | — |
| Operating income | $257.8M | $195.1M | $86.8M | $101.8M | $52.4M |
| Pretax income | $283.5M | $216.3M | $94.5M | $104.7M | $52.7M |
| Income tax expense | $69.2M | $52.4M | $23.1M | $21.6M | $13.2M |
| Net income | $214.3M | $163.9M | $71.4M | $83.1M | $39.5M |
| Balance Sheet | |||||
| Cash and equivalents | $709.2M | $517.6M | $137.6M | $298.4M | $171.4M |
| Current assets | $894.0M | $623.6M | $219.3M | $320.8M | $210.1M |
| Total assets | $1.1B | $851.4M | $470.1M | $375.6M | $237.8M |
| Current liabilities | $147.2M | $120.7M | $76.1M | $57.6M | $27.1M |
| Total liabilities | $149.7M | $123.8M | $82.2M | $75.2M | $31.0M |
| Stockholders' equity | $954.3M | $727.6M | $387.9M | $300.4M | $206.8M |
| Cash Flow Statement | |||||
| Cash from operations | $208.7M | $239.8M | $143.6M | $116.0M | $60.4M |
| Depreciation and amortization | $375,000 | $397,000 | $316,000 | $141,000 | $192,000 |
| Stock-based compensation | $24.8M | $22.3M | $14.2M | $7.9M | $6.1M |
| Capital expenditure | $58,000 | $556,000 | $231,000 | $29,000 | $1.0M |
| Free cash flow | $208.6M | $239.3M | $143.4M | $116.0M | $59.4M |
| Share repurchases | $25.3M | $0 | $0 | $6.9M | $12.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 122.4M · Free float 89.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.